Insider Buying Sparks Interest: Recent chatter on social media about Amylyx Pharmaceuticals has been fueled by a director's purchase of over $100,000 in stock. Many are interpreting this as a signal of confidence in the company’s future. This move has drawn significant attention amid a volatile market for biotech stocks.
Pipeline Potential Discussed: Conversations also highlight anticipation for a major Phase 3 readout expected in Q3 2026 for a key drug candidate. Enthusiasm is building around the potential impact on the company’s trajectory. However, some caution that clinical outcomes remain uncertain until data is released.
Note: This discussion summary was generated from an AI condensation of post data.
Amylyx Pharmaceuticals Insider Trading Activity
Amylyx Pharmaceuticals insiders have traded $AMLX stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AMLX stock by insiders over the last 6 months:
- GINA MAZZARIELLO (Chief Legal Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $246,148.
- KAREN FIRESTONE purchased 8,100 shares for an estimated $100,845
- CAMILLE L BEDROSIAN (Chief Medical Officer) sold 6,580 shares for an estimated $94,418
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Amylyx Pharmaceuticals Hedge Fund Activity
We have seen 99 institutional investors add shares of Amylyx Pharmaceuticals stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 8,331,188 shares (+273.3%) to their portfolio in Q3 2025, for an estimated $113,220,844
- COMMODORE CAPITAL LP added 4,075,478 shares (+inf%) to their portfolio in Q3 2025, for an estimated $55,385,746
- FIRST LIGHT ASSET MANAGEMENT, LLC added 3,355,882 shares (+inf%) to their portfolio in Q3 2025, for an estimated $45,606,436
- JANUS HENDERSON GROUP PLC added 2,536,233 shares (+inf%) to their portfolio in Q3 2025, for an estimated $34,467,406
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 1,998,721 shares (-68.1%) from their portfolio in Q3 2025, for an estimated $27,162,618
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,983,172 shares (-22.5%) from their portfolio in Q3 2025, for an estimated $26,951,307
- PARADIGM BIOCAPITAL ADVISORS LP added 1,900,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,821,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Amylyx Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $AMLX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/07/2025
- Goldman Sachs issued a "Buy" rating on 09/16/2025
- Guggenheim issued a "Buy" rating on 09/15/2025
- B of A Securities issued a "Buy" rating on 08/28/2025
To track analyst ratings and price targets for Amylyx Pharmaceuticals, check out Quiver Quantitative's $AMLX forecast page.
Amylyx Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $AMLX recently. We have seen 6 analysts offer price targets for $AMLX in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Andrew Fein from HC Wainwright & Co. set a target price of $20.0 on 11/07/2025
- Geoff Meacham from Citigroup set a target price of $20.0 on 10/17/2025
- Joel Beatty from Baird set a target price of $19.0 on 10/16/2025
- Geoff Meacham from B of A Securities set a target price of $16.0 on 10/03/2025
- Corinne Johnson from Goldman Sachs set a target price of $20.0 on 09/16/2025
- Seamus Fernandez from Guggenheim set a target price of $25.0 on 09/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
